In this file:


·         Efforts to Create ASF Vaccines Result in Cautious Optimism

·         Scientists welcome ‘promising’ ASF vaccine findings



Efforts to Create ASF Vaccines Result in Cautious Optimism


Dr. Volker Gerdts - Vaccine and Infectious Disease Organization

Farmscape for May 15, 2019


The Director of VIDO-InterVac says efforts aimed at developing vaccines to protect pigs from African Swine Fever are resulting in cautious optimism.


Scientists with VIDO-InterVac, in partnership with the Canadian Food Inspection Agency and partners in Kenya where African Swine Fever is present in pigs, have been working to develop vaccines to protect against the virus.


VIDO-InterVac Director Dr. Volker Gerdts notes several candidate vaccines are now being tested at the Canadian Food Inspection Agency's facility in Winnipeg.


Clip-Dr. Volker Gerdts-VIDO-InterVac:


We are using what is called a viral vector.


We're making a vaccine that is based on a harmless virus.


In this case we're using an Adenovirus.


We're manipulating the virus and we're inserting genes from the African Swine Fever into this Adenovirus and then use that for vaccination.


That's one of the promising approaches that is being used to control this disease.


Like many other diseases, it's also an approach that is also being used in humans to tackle important diseases such as HIV or Tuberculosis.


It's a very modern approach.


Over the years we've made over 30 different vaccine candidates and these are being tested as we speak in pigs.


We generated these vaccine candidates and they were injected into pigs and so soon these pigs will exposed to the disease and then we will see whether they are protected against the disease or not.





Scientists welcome ‘promising’ ASF vaccine findings


By Alistair Driver, Pig World (UK)

May 10, 2019


Scientists have welcomed what they describe as the first report of a ‘promising vaccine’ against ASF virus in wild boar.


The scientists from Spain demonstrated that oral immunisation of wild boar with an attenuated ASF virus of genotype II isolated in Latvia in 2017 conferred 92% protection against challenge with a virulent ASF virus isolate.


This protection translated to animal survival, but also to the absence of ASF-compatible clinical signs, pathological findings, and virus detection in target tissues.


“This is, to our knowledge, the first report of a promising vaccine against ASF virus in wild boar by oral administration,” the researchers said in an article in the Frontiers in Veterinary Science journal.


“Further studies should assess the safety of repeated administration and overdose, characterize long-term shedding and verify the genetic stability of the vaccine virus to confirm if (the vaccine) Lv17/WB/Rie1 could be used for free-ranging wild boar in ASF control programs.”


The researchers describe ASF as the most significant threat to the pig industry worldwide, having spread to more than 55 countries on three continents...